Minerva Neurosciences | NERV - Los Gastos De Explotación

Precio De Mercado
6.55
Cambio Diario
-0.99 -13.13%
Mensual
4.80%
Anual
254.05%
Q1 Expectativa
7.31




Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Adma Biologics USD 76.41M 6.8M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Alterity Therapeutics Limited AUD 7.78M 3M 2023-06
AstraZeneca USD 12.53B 4.16B 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Cipla INR 60.98B 1.06B 2025-12
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.29M 1.51M 2025-12
CSL USD 5.7B 2.82B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
J&J USD 18.97B 2.38B 2025-12
Merck USD 10.16B 558M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.8B 61M 2025-12
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 10.51B 1.21B 2025-12
Takeda JPY 1.02T 400.98B 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09